Since the first GWAS in AD emerged in 2007, GWAS has facilitated the exploration of the genetic architecture underlying amyloid-β (Aβ) and tau, and implicated a host of genetic variants associated with Aβ and tau biological processing (Khani et al., 2022). Here, MAPT is linked to Alzheimer disease.